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Background: CD26/dipeptidyl peptidase IV (DPPIV) is a multifunctional membrane protein with a key role in T-cell
biology and also serves as a marker of aggressive cancers, including T-cell malignancies.
Methods: Versican expression was measured by real-time RT-PCR and Western blots. Gene silencing of versican in
parental Karpas 299 cells was performed using transduction-ready viral particles. The effect of versican depletion on
surface expression of MT1-MMP was monitored by flow cytometry and surface biotinylation. CD44 secretion/
cleavage and ERK (1/2) activation was followed by Western blotting. Collagenase I activity was measured by a live
cell assay and in vesicles using a liquid-phase assay. Adhesion to collagen I was quantified by an MTS assay.
Results: Versican expression was down-regulated in CD26-depleted Karpas 299 cells compared to the parental
T-ALCL Karpas 299 cells. Knock down of versican in the parental Karpas 299 cells led to decreased MT1-MMP surface
expression as well as decreased CD44 expression and secretion of the cleaved form of CD44. Parental Karpas 299
cells also exhibited higher collagenase I activity and greater adhesion to collagenase I than CD26-knockdown
or versican-knockdown cells. ERK activation was also highest in parental Karpas 299 cells compared to
CD26-knockdown or versican-knockdown clones.
Conclusions: Our data indicate that CD26 has a key role in cell adhesion and invasion, and potentially in
tumorigenesis of T-cell lines, through its association with molecules and signal transduction pathways integral
to these processes.
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CD26/dipeptidyl peptidase IV (DPPIV) is a 110–115 kD
glycosylated protein that exists as a homodimer. It is a
multifunctional membrane protein with three domains:
extracellular, transmembrane, and cytoplasmic. It is widely
expressed on a number of tissues and can regulate tumor
growth and development [1-7]. The interaction of CD26/
DPPIV with other proteins, including collagen, fibronectin,
and caveolin-1, likely influences its involvement in cell* Correspondence: nam.dang@medicine.ufl.edu
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reproduction in any medium, provided the ormotility and invasion [8,9]. CD26 and its associated DPPIV
enzyme activity play a key role in T-cell biology, serving as
a marker of T-cell activation and participating in several
signaling pathways [10-13]. CD26 is also a marker of ag-
gressive cancers, including T-cell malignancies [14-20].
Interestingly, the cleaved form of CD26, which is present
in plasma, is inversely correlated with several aggressive
cancers [21].
Our previous work showed that CD26-depleted hu-
man T-anaplastic large cell lymphoma (T-ALCL) Karpas
299 cells were unable to form tumors in SCID mice [8],
and that CD26 expression on two T-cell lines increased
SDF-1-α-mediated invasion [22]. We were interested in
looking at CD26-associated gene products involved intd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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of genes involved in this pathway in parental Karpas 299
and CD26-depleted clones, and found that versican ex-
pression was associated with changes in CD26 level.
Microarray analysis revealed that mRNA level for versi-
can was considerably lower in CD26-depleted Karpas
299 cells than parental Karpas 299 cells (1:88). Although
mRNA levels for several other genes, including IGFBP3,
tenascin C, and SPOCK1, were also lower in CD26-
depleted cells than parental Karpas 299, Western blots
confirmed a difference in protein expression for versican
only, but not for the other three proteins. Versican is a
large chondroitin sulfate proteoglycan involved in the
regulation of adhesion, migration, invasion, and angio-
genesis [23]. Versican binds to ECM constituents includ-
ing type I collagen, fibronectin, and hyaluronan (HA)
[24] and a number of cell-surface proteins, including
CD44, integrin β1, and toll receptor 2 [25,26]. Versican
levels are elevated in most malignancies, and correlated
with poor patient outcome. Versican is secreted by peri-
tumoral stromal cells and also by the individual cancer
cells [27,28]. Four major isoforms exist that differ with
respect to the number and position of GAG molecules
attached, which are important for association with other
proteins. Of note is that the V0 and V1 isoforms are re-
ported to be the isoforms most closely associated with
cancers.
In the present paper, we examined in detail CD26 in-
volvement with cell migration and adhesion in T-cell
lines. Expression array analyses of genes involved in
extracellular matrix and adhesion pathways indicated
that versican expression was significantly higher in par-
ental T-ALCL Karpas 299 cells compared to CD26-
depleted Karpas 299 cells. To further investigate the
relationship between CD26 and versican, we conducted
knock down studies of versican in Karpas 299 cells and
evaluated for a potential effect on expression of signaling
proteins and adhesion. We found that the use of shRNA
to knock down versican expression in the parental
Karpas 299 cells resulted in both lower MT1-MMP tran-
scription and surface expression. To confirm that cell
behavior was consistent with the observed change in
MT1-MMP activity, several assays were performed; se-
cretion and cleavage of CD44, collagenase I activity, and
adhesion. In all three assays, parental Karpas 299 cells
exhibited higher activity compared to cells in which
CD26 or versican was knocked down. Finally, ERK acti-
vation, which is required for migration and invasion, was
also highest in the parental Karpas 299 cell line.
Methods
Reagents
Bovine serum albumin (BSA), polybrene (hexadimethr-
ine bromide), sodium dodecyl sulfate, glycine, sodiumdeoxycholate, trypsin, phosphate buffered saline, and di-
methyl sulfoxide were from Sigma Life Science, St.
Louis, MO. TX-100, NP-40, and Tween-20 were from
Fisher Scientific, USA. Puromycin was from Life Tech-
nologies, USA. Rat tail collagen and bovine skin colla-
gen were purchased from BD and Advanced Matrix,
respectively. GM6001, a general MMP inhibitor was
purchased from Calbiochem.
Cell culture
Karpas 299 cells were originally obtained from the
American Type Culture Collection (ATCC, Manassas,
VA) and maintained in RPMI-1640 (Hyclone, Logan,
UT). Karpas 299 cells depleted of CD26 have been de-
scribed previously [8]. All cell media contained 10%
fetal bovine serum (Hyclone), penicillin (100 u/ml) and
streptomycin (100 μg/ml).
Expression arrays
GEArray express human extracellular matrix and adhe-
sion molecule microarrays were carried out by SuperAr-
ray Bioscience Corporation on 10 μg total RNA isolated
from parental Karpas 299 cells and Dep1, a cell line defi-
cient in CD26 expression.
Real-time RT-PCR
Real-time RT-PCR was carried out on 10 ng total RNA
(RNeasy kit, Qiagen). SYBR Green-based real-time RT-PCR
was carried out using QuantiTect Primer Assays (Qiagen)
for CD26 (Hs_DPP4_1_SG), Versican (Hs_VCAN_1_SG),
and GAPDH (Hs_GAPDH_1_SG).
RT-PCR
RT-PCR was carried out on 10 ng of RNA isolated from
parental Karpas 299 cells, Dep1, and Dep2 using the
Titan One Tube RT-PCR system (Roche Applied Sci-
ence). The primers were described previously [29]. The
sizes of the amplification products were 405 bp for V0
(forward: 5′- TCAACATCTCATGTTCCTCCC-3′ and
reverse: 5′-TTC TTCACTGTGGGTATAGGTCTA-3′)
and 336 bp for V1 (forward: 5′-GGCTTTGACCAGTGC
GATTAC-3′ and reverse: 5′-TTCTTCACTGTGGGTA
TAGGTCTA-3′). The reverse transcription step was car-
ried out at 50° for 30 min, followed by denaturation for
2 min at 94°, amplified by 35 cycles (94° for 30 s, 55° for
45 s, 68° for 45 s) and elongated for 7 min at 68°.
Flow cytometry
Cells were washed once with staining buffer (PBS con-
taining 1% BSA) and incubated on ice for 30 minutes
with antibodies specific for the activity domain of MT1-
MMP (ab51074, Abcam, Cambridge, MA), then with
FITC goat anti-rabbit Ig at 0.125 μg/106 cells (BD Phar-
mingen). After washing with staining buffer twice, the
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MT1-MMP antibody was determined by titration.Gene silencing
Transduction ready viral particles for gene silencing of
versican (versican shRNA, Santa Cruz Biotechnology,
Inc., Santa Cruz, CA) were used to infect Karpas cells at
a ratio of 0.5 virus particles per cell. Cells were pelleted
the following day, resuspended in fresh media, and
48 hrs following transduction, puromycin was added at a
concentration of 2.5 ug/ml. Following selection, stable
clones were isolated by limiting dilution. Knockdown
was monitored by running whole cell lysates and/or
spent media on gels and probing with versican anti-
bodies as described in the Western Blot section.Cell lysis
Cells were lysed using RIPA (1% NP40, 0.5% DOC, 0.1%
SDS, 150 mM NaCl, 50 mM TrisCl, pH 8.0) or TX100
buffer (50 mM TrisCl, pH 8, 0.15 M NaCl, 1% TX-100)
containing a protease/phosphatase inhibitor cocktail
(Pierce, Rockford, IL). Protein concentration was deter-
mined using the bicinchoninic acid protein assay reagent
(Pierce).Isolation of vesicles from serum free media
Cells (8 × 106) were grown in serum free media for
48 hours, followed by centrifugation at 600 ×g for
15 min, then 1500 × g for 15 min, and the resulting
supernatant was subsequently centrifuged at 100,000 × g
for 1 hr at 4°C. Pelleted vesicles were suspended in PBS
and assayed for protein [30].Western blots
Equal amounts of protein were run on 5.0, 7.5% or 10%
polyacrylamide gels. For detection of versican, samples
were combined with sample buffer without reducing
agent. Following transfer, blots were blocked, then
probed with one of the following antibodies: anti-CD26
(AF1180) and anti-CD44H (clone 2C5) were from R &
D Systems, Inc., Minneapolis, MN; anti-versican (clone
2B1, Seikagaku, Tokyo, Japan); and anti-MT1-MMP
(ab38971, Abcam). Anti-phospho-p44/42 MAPK (Erk ½)
and anti-p44/42 MAPK (Erk ½) were from Cell Signaling
Technology, Inc; anti-integrin alpha 5 chain (BD, cat#
610633). Precision Plus Protein Standards (Bio-Rad La-
boratories, Hercules, CA) were run to estimate sizes of
proteins of interest. Horseradish peroxidase-conjugated
secondary antibodies and the detection reagent, Super-
Signal West Dura Extended Duration Substrate, were
from Pierce. Films were scanned using an Image Quant
400 (GE Healthcare, Piscataway, NJ).Biotinylation and immunoprecipitation
Cells were suspended in PBS (2.5 × 107/ml) and incu-
bated with 200 μl of 10 mM EZ-Link® Sulfo-NHS-LC-
Biotin/ml cells for 30 min on ice. The cells were then
washed 3× with PBS containing 100 mM glycine. Fol-
lowing lysis in TX100 buffer, 1 mg lysate was applied to
a Streptavidin- Agarose spin column (Pierce), and fol-
lowing extensive washing, bound proteins were eluted
with 2× sample buffer and heating at 100°C for 5 min.
Eluates were run on 7.5% acrylamide gels and probed
with anti-MT1-MMP antibody.
Collagen degradation in cultured cells
Collagen I degradation was monitored in live cells mi-
grating through a native 3D collagen substrate. DQ™ col-
lagen, type I from bovine skin, fluorescein conjugate
(Molecular Probes) was copolymerized with rat-tail col-
lagen type I, in RPMI media without phenol red (Life
Technologies). After incubation for 48 hrs at 37°C, solid
phase collagen and cells were pelleted and the super-
natant analyzed for FITC using a Perkin-Elmer Victor3
V multilabel counter [31].
Collagen degradation in vesicles
The EnzChek collagenase assay (Life Technologies) was
used to evaluate activity in vesicles isolated from condi-
tioned media. In this assay, DQ™ collagen, type I from
bovine skin, fluorescein conjugate (Molecular Probes)
was used as substrate and the incubation was carried out
at room temperature as described by the manufacturer.
Each well of a 96 well plate contained 4.5 μg vesicle pro-
tein. Fluorescence was detected using the Perkin-Elmer
instrument.
Adhesion assays
Adhesion assays were carried out essentially as described
[8]. Cells (5 × 105/well) were seeded into 12 well colla-
gen I coated plates and incubated overnight. Unattached
cells were removed, plates were washed three times with
PBS and the adhesive cells remaining were quantified
using the MTS assay. The total cell number was deter-
mined using uncoated wells and serial dilutions were
used to construct a standard curve to convert absorb-
ance at 490 nm to cell number.
Results
Model showing idealized scheme for interaction of
signaling molecules in parental Karpas 299 cells
Figure 1 depicts a simplified scheme for molecules be-
lieved to be involved in CD26 enhanced invasion. In this
proposed model for parental Karpas 299 cells, CD26 is
shown bound to the cell membrane. Results from our
microarray analysis indicated that in CD26-depleted cells,













Figure 1 Model for CD26 regulation of adhesion and downstream signaling. In this simplified scheme, CD26 is shown bound to the cell
membrane. Versican is also depicted in the membrane, but is also secreted and is a constituent of the extracellular matrix. CD44 and HA are
bound to versican, but CD44 is also bound to MT1-MMP, which can itself cleave CD44, resulting in CD44 secretion. Secretion of the cleaved CD44
is necessary for localization of MT1-MMP at the invadopodia where it digests collagen I, a constituent of the extracellular matrix. In addition, Erk
(1/2) activation occurs in the parental Karpas cells and has been reported to be required for migration, invasion, and CD44 upregulation. This
model is intended to be a working hypothesis of the relationship between the proteins shown here.
Table 1 Oligo GE Array microarrays indicate that versican
mRNA expression is higher in CD26-expressing cells than
in CD26-depleted cells (Dep1)
Unigene RefSeqNo Symbol Dep1 Karpas Karpas/Dep1
Hs.544577 NM_002046 GAPDH 253.7 141.5 0.56
Hs.443681 NM_004385 VCAN 0.68 60.12 88.4
GEArray express human extracellular matrix and adhesion molecule
microarrays were carried out by SuperArray Bioscience Corporation on 10 μg
total RNA isolated from parental Karpas 299 cells and Dep1, a cell line
deficient in CD26 expression.
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component and is involved in diverse activities, including
adhesion, proliferation, migration, and angiogenesis. MT1-
MMP is a membrane MMP and is also involved in these
activities. It is one of the few MMPs that can degrade dir-
ectly collagen I, a component of the extracellular matrix.
CD44 binds to both versican and MT1-MMP, which is
able to cleave CD44. It is thought that cleavage and release
of CD44 from the membrane is required for the relocaliza-
tion of MT1-MMP to the invadopodia, where it binds to
collagen I, leading to invasion of the extracellular matrix.
Relocation to the invadosome may occur in vesicles (or
exosomes). Activation of Erk (1/2) is also shown here,
since it is reported to form a positive feedback loop with
MT1-MMP and has been shown to regulate invasive
activity.
Decreased expression of versican is associated with CD26
depletion in human T-anaplastic large cell lymphoma Kar-
pas 299
Our previous work showed that depletion of CD26 in
Karpas 299 cells resulted in loss of cell adhesion to the
extracellular matrix and decreased tumorigenicity in a
SCID mouse xenograft model [8]. To identify CD26-
associated gene products potentially involved in cell ad-
hesion processes, we performed expression microarray
analysis of human extracellular matrix and adhesion
molecules with RNA isolated from parental Karpas 299
and the CD26-depleted Karpas 299 cell line Dep1 [8].
Our data indicated that expression of versican was ap-
proximately 90-fold higher in the parental Karpas 299
cells compared to CD26-depleted Karpas 299 cells
(Table 1).Real-time RT-PCR and Western blots were subse-
quently carried out to confirm differential expression of
versican in parental Karpas 299 cells and the two CD26-
depleted Karpas 299 cell lines Dep1 and Dep2 [8]. RNA
was isolated from Karpas 299, Dep1, and Dep2 cells, and
SYBR Green based real-time RT-PCR was performed
using QuantiTect Primer Assays. Down-regulation of
versican was confirmed in CD26 depleted cells, with an
80-fold and 103-fold enrichment for parental Karpas
299 compared to Dep1 and Dep2, respectively (Table 2).
Western blot analyses also confirmed that versican ex-
pression was higher in parental Karpas 299 as compared
to Dep1 and Dep2 (Figure 2A). RT-PCR using V0 and
V1 specific primers were used to confirm this as shown
in Figure 2B.
Enhanced expression of MT1-MMP is associated with
CD26 and versican in Karpas 299
MT1-MMP (MMP14) plays a critical role in the process
of cell motility and invasion, with its deletion in tumor
cells resulting in the loss of both in vitro and in vivo in-
vasive activity [32]. We therefore examined its status in
parental Karpas 299 and the CD26-depleted Karpas 299
Table 2 Real-time RT-PCR was used to confirm Versican
expression
GAPDH Avg Ct Karpas/Dep1 Karpas/Dep2
Karpas 17.74 - -
Dep1 16.70 0.49 -
Dep2 16.72 - 0.49
CD26
Karpas 20.93 - -
Dep1 23.95 8.11 -
Dep2 24.05 - 8.69
Versican
Karpas 25.51 - -
Dep1 31.83 80 -
Dep2 32.20 - 103
RNA was isolated from Karpas 299 cells and two clones, Dep1 and Dep2, in
which CD26 is depleted. SYBR Green-based real-time RT-PCR was carried out
on 10 ng total RNA using QuantiTect Primer Assays for CD26, Versican,
and GAPDH.
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the effect of versican depletion in the T-ALCL Karpas
299 cell line independent of CD26 status, we established
a number of versican knock down Karpas 299 lines, as
described in Materials and Methods and shown in
Figure 2.
Since only MT1-MMP expressed on the cell surface
mediates degradation of the extracellular matrix [32], we
next evaluated its surface expression by both cell surface
biotinylation and flow cytometry analysis, as described





















Figure 2 Confirmation of Versican expression in Karpas 299 cells and
blots confirmed versican expression in Karpas cell lines and clones resulting
shRNA. Whole cell lysates (30 μg) of Karpas, Dep1, Dep2, and two clones d
6RD3 were run on 7.5% gels. The top of the gel and 250 kD marker are ind
followed by anti-mouse HRP at 1:10,000 dilution. B. RT-PCR using V0 and V
parental Karpas 299 cells was used but barely detectable when RNA from D
and RT-PCR were obtained from two independent experiments.in collagen I coated wells to stimulate MT1-MMP
expression [33]. Our data indicated that a higher per-
centage of parental Karpas 299 cells exhibited surface
expression of MT1-MMP than CD26-depleted Dep1 or
versican-knock down clone 6RD3 (Figure 3A).
Meanwhile, flow cytometry studies also demonstrated
that the presence of collagen induced greater surface ex-
pression of MT1-MMP in all cells tested (Figure 3B). Im-
portantly, a higher percentage of parental Karpas 299 cells
expressed surface MT1-MMP than Dep1 or 6RD3 clones
in the presence or absence of collagen. Of note is the fact
that our experiments consistently found MT1-MMP to be
expressed at relatively low levels on the cell surface, find-
ings which were consistent with previous work demon-
strating that only small amount of MT1-MMP is expressed
on the cell surface at any one time [34].
Enhanced CD44 expression is associated with CD26 and
versican in Karpas 299
MT1-MMP has been reported to associate with several
membrane-associated and cytosolic proteins, including
CD44 [35]. Interaction of MT1-MMP with CD44 leads
to the cleavage of CD44 and facilitates migration by in-
directly linking MT1-MMP to the cytoskeleton [35,36].
Our present work demonstrated that expression of
CD44 in total cell lysates (Figure 4A) and secretion of its
cleaved form in conditioned media (Figure 4B) were
higher in parental Karpas 299 as compared to the CD26-
depleted Dep1 and versican-depleted 1A12 and 6RD3
clones. Since PMA has been shown to increase CD44










































in CD26-depleted and Versican-depleted Karpas cells. A. Western
from knockdown of versican in parental Karpas 299 cells using
erived from knock down of versican in parental Karpas cells, 1A12 and
icated. Blots were probed with anti-versican antibody at 1:100 dilution,
1 specific primers show product was present when RNA from the





























Figure 4 CD44 expression/secretion of cleaved form is higher in pare
lysates (30 μg) from cells grown on collagen I plates in the presence or ab
(75 μg) isolated from cells grown on collagen I plates for 24 hr. Samples w
followed by anti-mouse HRP. Of note is that intact CD44 migrates as a 100



















































Figure 3 Surface expression of MT1-MMP is higher in Karpas
parental cells than in Dep1 (CD26 depleted) or 6RD3 (versican
depleted). A. Cells were grown overnight on collagen I plates, then
biotinylated using an impermeable reagent. Lysates (1 mg protein)
were applied to streptavidin-agarose spin columns, washed, and
eluted with sample buffer. Eluates were run on 7.5% SDS gels,
transferred to nitrocellulose, and probed with MT1-MMP antibodies.
B. Flow cytometry of cells grown with and without collagen I. Data
are representative of two independent experiments for panel A and
for panel B.
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our studies in the presence or absence of PMA. In our
experimental system, PMA had only a slight enhancing
effect on the expression and secretion of CD44.
Enhanced collagenase I activity is associated with CD26
and versican in Karpas 299 cells
Previous work has demonstrated an association between
MT1-MMP and enhanced collagen I degradation [32,41].
We next conducted two separate assays for collagenase I
activity as described in Materials and Methods, one using
a solid phase assay in which collagen I degradation was
monitored in live cells (Figure 5A), and the other using a
liquid-phase assay with vesicles isolated from conditioned
media (Figure 5B). In both types of assays, parental Karpas
299 cells exhibited a higher level of collagenase I activity
than Dep1 or 6RD3 clones.
Adhesion to collagen I is highest in the parental Karpas
299 cell line
Adhesion to collagen I was compared for the parental
Karpas 299 cells, the CD26-depleted cells (Dep1) and
versican-depleted cells (6RD3) in precoated 12 well plates.
Our findings indicated that the versican-expressing paren-
tal Karpas 299 cells exhibited much greater adhesion to
collagen than the versican-depleted Dep1 and 6RD3 cell
lines (Figure 6).
Erk(1/2) activation is highest in the parental Karpas 299
cell line
Erk (1/2) activation is required for CD44 [42,43] expres-
sion and cell migration and is induced by overexpression
of MT1-MMP [44]. In addition, MT1-MMP expression
activates Erk (1/2), which then leads to upregulation of
MT1-MMP, creating a positive feedback loop [33]. To
further explore the mechanism involved in MT1-MMP























ntal Karpas 299 cells than in Dep1 or 6RD3 cells. A. Whole cell
sence of 10 ng/ml PMA for 24 hr. B. Concentrated conditioned media
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Figure 5 Karpas 299 cells and vesicles exhibit greater collagenase I activity than either Dep1 or 6RD3 cells. A. Collagen I degradation
was monitored in live cells migrating through a native 3D collagen substrate. FITC-collagen type I from bovine skin was copolymerized with
rat-tail collagen I. After 48 hr, cells and solid phase collagen were pelleted and the supernatant analyzed for FITC release. B. Collagen I degrad-
ation was also measured in vesicles isolated from conditioned media of cells grown for 48 hrs on collagen I. Two independent assays are shown
for the intact cells (A) and three independent assays for the vesicles (B). Error bars are standard error of the mean.
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expression of MT1-MMP, phosphorylated Erk (1/2), and
integrin α5 in vesicles isolated from the conditioned
medium was determined by Western blot (Figure 7). We
had previously observed that activated Erk (1/2) and
MT1-MMP were present in the conditioned media (data
not shown) and others have shown that MT1-MMP is
present in vesicles isolated from the spent media of
endothelial [45], fibrosarcoma, and melanoma cells [46].
We found that the expression of MT1-MMP was higher
in parental Karpas 299 cells than in the CD26-depleted

















Figure 6 Adhesion assays show that Karpas 299 cells adhere to collag
expressing, versican-depleted, 6RD3 cells. Cells (5 x 105/well) were seed
Following removal of non-adhesive cells, the cells remaining were quantifie
uncoated wells and serial dilutions were used to construct a standard curv
standard error of the mean. Data are representative of three independent eErk (1/2) followed the same pattern, which is consistent
with observations for actively migrating cells [38]. In
contrast the level of the α5 integrin appeared to be simi-
lar in all cells.
Discussion
In this paper, we have focused on the differential expres-
sion of versican in CD26-expressing Karpas 299 cells as
compared to a CD26-depleted clone and the associated
changes in various cellular activities as related to tumori-
genesis. As a point of reference, we presented a working
model at the beginning of the paper. The emphasis isDep1 6RD3
en I to a greater extent than CD26-depleted, Dep1, or CD26-
ed into 12 well collagen I coated plates and incubated overnight.
d using the MTS assay. The total cell number was determined using


















Figure 7 Erk(1/2) activation is highest in the parental Karpas
299 cell line. Cells (8 x 106) were grown in serum free media for
48 hrs, centrifuged at low speed to remove cells and debris, then at
100,000 x g for 1 hr. Vesicles were suspended in PBS and assayed for
protein. Equal amounts of protein (5 μg) were loaded in each well
of a 7.5% SDS gel. Following transfer to nitrocellulose, blots were
probed with anti-MT1-MMP antibody (top) or anti-phospho-p44/42
MAPK antibody (middle), stripped, and reprobed with anti-p44/42
MAPK antibody (next to bottom). The blot was also probed with
anti-α5 integrin antibody (bottom). Data are representative of two
independent experiments.
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have several important activities which could account for
the ability of CD26-expressing Karpas 299 cells to form
tumors in SCID mice as opposed to the inability of CD26-
deficient Karpas 299 cells to develop tumors in the same
animal model [8]. We do note that this simplified model
does not take into account the complex roles that MT1-
MMP and other MMPs play in cancer progression. For ex-
ample, in addition to degrading the extracellular matrix,
MT1-MMP plays an important role in tumor angiogenesis
[47] through upregulation of VEGF [48] and immunoreg-
ulation through its effect on the release and activation
of cytokines such as TGF-β, a well-known suppressor of
T-lymphocyte reaction against cancer [49].
In addition to the difference in versican expression,
there were differences in adhesion, MT1-MMP surfaceexpression, CD44 cleavage and secretion, and collage-
nase I activity. Although CD26 is known to bind both
collagen [50,51] and fibronectin [52], versican also binds
these proteins, and can further strengthen the binding of
CD26-expressing cells to the extracellular matrix. This
conclusion is consistent with our observation that MT1-
MMP surface expression was increased in cells bound to
collagen I. Since localization of MT1-MMP to the cell
membrane is required for its ability to degrade the extra-
cellular matrix [32], the decreased surface expression of
MT1-MMP associated with loss of versican would be
predicted to have an effect on cell motility, and possibly,
tumorigenesis by interfering with the ability of tumor
cells to interact with the microenvironment.
Our present work also established a relationship be-
tween CD44, CD26 and versican, with CD44 cleavage/
secretion being higher in parental Karpas 299 cells than in
cells depleted of versican (both CD26-depleted cells as
well as CD26-expressing/versican depleted cells). Inter-
action with and cleavage of CD44 by MT1-MMP has been
shown to facilitate migration by indirectly linking MT1-
MMP to the actin cytoskeleton [35,36]. The function of
MT1-MMP is regulated in large part by its localization;
MT1-MMP activity has been observed at invadopodia
[53-55], lamellipodia [35], and focal adhesions [56], with
CD44 cleavage and secretion appearing to play a role in
the localization of MT1-MMP to the invadopodia [35].
Our data also indicated a higher level of ERK activation
in parental Karpas 299 cells compared to CD26-depleted
or CD26-expressiong/versican-depleted clones. ERK acti-
vation is required for migration, invasion [44,57,58], and
CD44 upregulation. The requirement for matrix proteins
along with ERK activation suggests that integrins may be
involved in MT1-MMP regulation [59], a conclusion that
is further supported by colocalization of integrins with
MT1-MMP in vesicles [46,60] and the existence of
common recycling pathways [61]. In a recent study,
intracellular trafficking of MT1-MMP was found to be
coupled with trafficking of integrin α5, ERK activation,
and phosphorylation of MT1-MMP at Thr567 [38]. We
also detected these three proteins in vesicles isolated from
conditioned media; MT1-MMP and phosphorylated ERK
were highest in the parental Karpas 299 cells, whereas the
amount of α5 integrin was approximately the same in all
three cell lines.
Although regulation of versican expression is not well
understood, it has been shown to be a target of Wnt sig-
naling, regulated by the phosphatidylinositol 3-kinase
(PI3K) pathway in human embryonic carcinoma cells
[62]. It is possible that it is also regulated by this path-
way in Karpas 299 cells, since activated Akt/PKB is
higher in the parental Karpas 299 cells than in CD26-
depleted or versican-depleted cells (unpublished obser-
vations, author).
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can also form heterodimers with fibroblast activation
protein alpha (FAP or Seprase) [63], which shares 48%
homology with CD26 [64], but unlike CD26, can digest
collagen. Although this protein complex has been de-
tected at the invadopodia of migrating fibroblasts [65],
we did not explore the role of Seprase activity in the
collagenase I activity of Karpas 299 cells. However, our
Western blot assays for Seprase did not detect a differ-
ence among parental Karpas 299 cells, Dep1, and 6RD3
(data not shown). While it has been suggested that
CD26 and related proteins, such as FAP, may serve as
valuable biomarkers for selected malignancies, better in-
depth understanding of the functional roles of these
molecules in particular tumor types and their associated
microenvironment will improve our knowledge of the
implications of their expression in tumor behavior [66].
Conclusions
In summary, our data suggest that CD26 has a key role
in cellular adhesion and invasion through versican and
MT1-MMP expression as well as downstream signaling
molecules involved in these processes. The expression of
versican in Karpas 299 parental cells is likely responsible
for their increased adhesion to the extracellular matrix,
which is necessary for cellular interaction with ECM com-
ponents and is also required for migration. The difference
in the adhesiveness of the parental Karpas 299 cells and
their CD26-deficient (and therefore versican deficient)
counterpart, Dep1, may account for the difference in
tumorigenicity previously observed in SCID mice [8].
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